日韩AV资源站,AV激情亚洲男人天堂

Global Biopharma Layoffs May 2026 Layoffs Biopharma layoffs in 2026 continue to reshape the industry as companies including Takeda, Novartis, Replimune, Passage Bio and Autolus Therapeutics cut jobs, restructure operations and reduce costs amid pipeline setbacks, strategic reorganizations and market pressures.
Global Biopharma Layoffs March 2026 Layoffs Global Biopharma companies including Merck, Baye, and Novartis announce workforce reductions in March 2026 as part of cost-saving and strategic realignments, impacting research, technology, and leadership roles across their operations.
Novartis Full Year 2025 Financial Report Financial statements Novartis' 2025 financial results show strong growth, driven by innovations like Kisqali, Pluvicto, and Leqvio. With a strong pipeline and key market expansions, the company is well-positioned for future growth despite patent challenges.
Global Biopharma Layoffs September 2025 Layoffs The biopharmaceutical industry sees major september layoffs, with companies like Novartis cutting jobs amid restructurings, trial setbacks, and M&A activity.
Novartis' Triple Phase III Study Success: Dual-Action Anti-BAFF-R Monoclonal Antibody Triumph Novartis Novartis' anti-BAFF-R antibody Ianalumab achieves breakthrough results in three Phase III trials for Sj?gren’s syndrome and immune thrombocytopenia, paving way for new autoimmune therapies.
2025 H1 Global Pharma Earnings Panorama Financial statements A comprehensive analysis of global pharma earnings in H1 2025, highlighting innovation-driven growth, key players like Novartis, Novo Nordisk, AstraZeneca, Sanofi, and BeiGene, and trends shaping the industry’s future.
Novartis Q2 2025 Earnings Report Financial statements Novartis reported strong Q2 2025 results with double-digit revenue growth, key product successes, and promising R&D breakthroughs. The company's innovation and strategic focus position it for sustained long-term leadership.
Pharma's $158B U.S. Manufacturing Surge Market Trend Major pharmaceutical companies pledge $158 billion to U.S. manufacturing to sidestep tariff threats, funding facilities from California to North Carolina. Lilly, J&J, Novartis, Roche and Regeneron drive billions in reshoring investments, creating thousands of jobs.
Novartis's Q1 2025 Financial report Market Trend Novartis reports strong Q1 2025 results with 12% sales growth, 27% core operating income increase, major FDA approvals, and raised full-year guidance amid robust innovation and strategic execution.
2024 Global Top 10 Pharmaceutical Companies Market Trend The 2024 global ranking of the top 10 pharmaceutical companies showcases the continued strength of industry leaders like Johnson & Johnson, Roche, and Merck. Pfizer, AstraZeneca, and Eli Lilly also maintain strong positions with impressive growth and strategic investments.

<Pre12 3 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

国产91视频久久,亚洲综合色图在线观看,五月天操逼网,日韩色色AV,青青在线A片,亚洲最大色在线观看,欧美熟妇丝袜诱惑,青青操逼视频,日韩无码操出水